Ireland
--:--IST
Starting soon Observational

Robotic Minimally Invasive Benign Hysterectomy Post-market Clinical Study With the DEXTER Robotic System

NCT07746531 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2026-08-07
Last updated
2026-08-05

Condition(s) studied

Hysterectomy, Benign Uterine Diseases

Investigational drug(s) / intervention(s)

benign hysterectomy

benign hysterectomy: Robotic-assisted and laparoscopic hysterectomy for benign disease with the DEXTER robotic surgery system.

Study summary

The purpose of this post-market, observational study is to collect real-world data under anticipated conditions of use that demonstrates that the device performs as intended (accurate, precise control of surgical instruments) in patients undergoing robotic-assisted and laparoscopic hysterectomy for benign disease.

Eligibility

Sex
FEMALE
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient is ≥ 22 years of age at time of enrollment/consent * Patient is planned to undergo robotic-assisted and laparoscopic hysterectomy for benign disease * Patient agrees to perform the 6-week follow-up assessment as per standard of care Exclusion Criteria: * Any planned concomitant procedures (not including salpingectomy and/or oophorectomy) * Diagnosed malignant disease on reproductive organs * Uterus myomatous with fibroid \> 10cm

Primary outcome measure(s)

  • Primary safety outcome — up to 42 days after surgery
    Occurrence of Clavien-Dindo grades III-V adverse events
  • Primary efficacy outcome — Intraoperative
    Successful completion of the DEXTER-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach

Trial sites (2)

FacilityCityRegionStatus
Cypress surgery center Wichita Kansas
Memorial Hermann-Texas Medical Center - UT Health Houston Houston Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07746531 on ClinicalTrials.gov ↗ ← All trials in the USA